Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study

Aaron T. Gerds, Srđan Verstovšek, Alessandro M. Vannucchi, Haifa Kathrin Al‐Ali, David Lavie, Andrew Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela Lazaroiu, Miklós Egyed, María Laura Fox, Donal P. McLornan, Andrew C. Perkins, Sung‐Soo Yoon, Vikas Gupta, Jean‐Jacques Kiladjian, Nikki Granacher, Sung‐Eun Lee, Luminita Ocroteala, Francesco Passamonti, Claire Harrison, Stephen T. Oh, Barbara Klencke, Jing Yu, Rafe Donahue, Jun Kawashima, Ruben A. Mesa